Chemical Messenger News and Research

RSS

NIH-funded study raises hope for recovery of some adult patients with brain disorder

Scientists have reversed behavioral and brain abnormalities in adult mice that resemble some features of schizophrenia by restoring normal expression to a suspect gene that is over-expressed in humans with the illness.

23 May 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Researchers from the Royal College of Surgeons in Ireland have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus could potentially benefit Irish patients who suffer from the condition.

8 May 2013

Review finds drugs, vitamin supplements may not help prevent cognitive decline in seniors

A review of published research has found no evidence that drugs, herbal products or vitamin supplements help prevent cognitive decline in healthy older adults.

16 Apr 2013

Academic medical centers launch ASD sub-registry within ResearchMatch

Each year, only five percent of the estimated 1.5 million children with an autism spectrum disorder in the US participate in clinical research studies. This is in stark contrast to pediatric cancer studies, which have a nearly 90 percent enrollment rate - a rate that has helped advance treatment and outcomes for childhood cancers substantially in the last decade.

27 Mar 2013

Transfusion of older blood adversely affects patients undergoing cardiac surgery or critical care

Transfusion of donated blood more than three weeks old results in impaired blood vessel function, a new study of hospital patients shows.

11 Mar 2013

CELF6 genetic mutation may underlie common behaviors seen in people with autism

Scientists at Washington University School of Medicine in St. Louis have identified a genetic mutation that may underlie common behaviors seen in some people with autism, such as difficulty communicating and resistance to change.

14 Feb 2013

Parkinson’s: an interview with Steve Ford, CEO of Parkinson’s UK

Parkinson’s disease is a neurological condition that is caused when brain cells, that produce the chemical messenger dopamine, start to die.

24 Dec 2012

LED light instantly triggers or reverses depression-like behavior in rodents

A specific pattern of neuronal firing in a brain reward circuit instantly rendered mice vulnerable to depression-like behavior induced by acute severe stress, a study supported by the National Institutes of Health has found. When researchers used a high-tech method to mimic the pattern, previously resilient mice instantly succumbed to a depression-like syndrome of social withdrawal and reduced pleasure-seeking - they avoided other animals and lost their sweet tooth.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Suvorexant may bring help for people with insomnia

A new drug may bring help for people with insomnia, according to a study published in the November 28, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Nov 2012

Short instance of moderate exercise improves memories in older adults with MCI

A short burst of moderate exercise enhances the consolidation of memories in both healthy older adults and those with mild cognitive impairment, scientists with UC Irvine's Center for the Neurobiology of Learning & Memory have discovered.

28 Nov 2012

Overexpressed enzyme contributes to development of preeclampsia

Preeclampsia is a serious complication of pregnancy and the major cause of death for both mother and child in Europe and the U.S. It affects about one in 20 pregnancies. The main symptoms are high blood pressure and protein in the urine.

26 Nov 2012

Dopamine improves long-term memory

The feel-good hormone dopamine improves long-term memory. This is the finding of a team lead by Emrah D-zel, neuroscientist at the German Center for Neurodegenerative Diseases and the University of Magdeburg.

9 Nov 2012

FDA accepts Merck’s suvorexant NDA for standard review

Merck, known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company's investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).

9 Nov 2012

Researchers create mouse model that reproduces brain chemical changes associated with AD

Researchers at Western University have created a mouse model that reproduces some of the chemical changes in the brain that occur with Alzheimer's, shedding new light on this devastating disease.

11 Oct 2012

Researchers uncover molecular and clinical role of irisin in humans

A research team led by Dr. Christos Mantzoros, MD, PhD, at Beth Israel Deaconess Medical Center, Harvard Medical School, has published new findings elucidating the molecular and clinical role of FNDC5/irisin in humans.

1 Oct 2012

Interleukin-6 could affect hunger and satiety

Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have identified a molecule in the immune system that could affect hunger and satiety. The researchers hope that new treatments for obesity will benefit from this finding.

24 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Scientists discover biological marker that may help identify patients’ response to antidepressants

Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

7 Aug 2012

Allergies may reduce risk of brain cancer

New research adds to the growing body of evidence suggesting that there's a link between allergies and reduced risk of a serious type of cancer that starts in the brain. This study suggests the reduced risk is stronger among women than men, although men with certain allergy profiles also have a lower tumor risk.

3 Aug 2012